Physician profile
Lori England Wright
NPI 1477536829
$2,594.90
in general payments reported to CMS, 2019-2025
32 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $197 · 2021: $251 · 2022: $488 · 2023: $419 · 2024: $517 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.22 | 2021-2025 | |
| Novo Nordisk INC | $292.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $261.61 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $251.61 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $222.11 | 2019-2024 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Allergan, INC. | $130.24 | 2019-2020 | |
| Insulet Corporation | $118.96 | 2024 | Omnipod |
| Axsome Therapeutics, INC. | $89.73 | 2024 | Auvelity |
| Pfizer INC. | $74.18 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.71 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $70.62 | 2019-2021 | |
| Amarin Pharma, INC. | $62.35 | 2019-2021 | |
| Amgen INC. | $60.46 | 2020-2023 | Otezla, Repatha |
| Dexcom, INC. | $54.97 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $54.35 | 2022-2023 | Mounjaro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $44.62 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $40.67 | 2022 | |
| Hologic Sales and Service, LLC | $34.61 | 2023 | Aptima |
| Novartis Pharmaceuticals Corporation | $34.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.44 | 2022-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.85 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.51 | 2022 | |
| Biogen, INC. | $25.81 | 2024 | |
| Valeritas, INC. | $25.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.88 | 2019 | |
| Mylan Specialty L.P. | $18.67 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.75 | 2024 | Caplyta |
| Sanofi Pasteur INC. | $15.42 | 2024 | |
| Cranial Technologies, INC | $14.72 | 2020 | |
| Exact Sciences Corporation | $14.68 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.30 | 2022 | |
| Astellas Pharma US INC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori England Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.